Novel Biomarkers in Chronic Airway Diseases

NCT ID: NCT00849836

Last Updated: 2009-02-24

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

30 participants

Study Classification

OBSERVATIONAL

Study Start Date

2009-02-28

Study Completion Date

2010-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is:

* To define The differences of bio-chemical phenotypes in chronic airway inflammatory diseases.
* To identify novel biomarkers in chronic airway inflammatory diseases as a screening, diagnostic, or monitoring marker.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Asthma COPD

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Acute exacerbation

No interventions assigned to this group

Stable disease

No interventions assigned to this group

Healthy control

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* \> 18 years olds
* Both sexes
* Asthma or COPD was diagnosed according to the criteria of the American Thoracic Society, GINA, GOLD guideline
* Acute exacerbation was defined by the criteria of the American Thoracic Society, GINA, GOLD guideline
* For stable disease, none of the subjects had received inhaled or oral corticosteroids or any other anti-inflammatory drugs, had an exacerbation history in the previous 6 months
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Chonbuk National University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Chonbuk National University Medical School

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Chonbuk National University Medical School

Jeonju, , South Korea

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

South Korea

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

So Ri Kim, MD, PhD

Role: CONTACT

82-63-250-2475

Yong Chul Lee, MD, PhD

Role: CONTACT

82-63-250-1664

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

So Ri Kim, MD, PhD

Role: primary

Yong Chul Lee, MD, PhD

Role: backup

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

RCPD

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Biomarker in Lung Diseases
NCT00989846 UNKNOWN
Markers of COPD Exacerbations
NCT05315674 RECRUITING